Posted by Michael Wonder on 23 Jan 2025
Medexus announces FDA approval of Grapafex (treosulphan) for injection
22 January 2025 - Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed US$100 million within five years after commercial launch.
Medexus Pharmaceuticals is pleased to provide a business update regarding the successful completion of the regulatory review process for Grafapex (treosulfan) for injection with the US FDA.
